Implant surfaces, texture and the TGA landscape

For years, texture was a technical preference. A rough surface, the theory went, helped a device stay put and perhaps lowered capsular contracture in some placements. Then breast implant-associated anaplastic large cell lymphoma moved from a rare paper to a public Australian regulatory event. Patients who had never heard of a surface grade suddenly wanted to know what their implants felt like to a pathologist.

The Therapeutic Goods Administration did not ban “texture” as a folk category. It acted on specific devices and risk signals. That distinction matters. A consult that says “we only use safe implants” is reciting a lullaby. A consult that names the product, the surface classification and the current listing is doing the work.

What a surface is trying to do

A smooth implant has a relatively even elastomer shell. It can move a little in its pocket. That movement is why some surgeons like it for a mobile, breast-like feel, and why others worry about malposition in a loose pocket.

A textured implant has a surface designed to encourage tissue adherence. Macro-textured devices were the most aggressive version of that idea. Finer textures sit on a spectrum. Polyurethane-coated implants are a different surface story again: a foam-like coating with its own history, advocates and monitoring requirements.

None of these surfaces is “organic”. All of them are manufacturing decisions. The body answers with a capsule — a scar envelope — whatever the marketing adjective.

Why Australia changed its mind in public

BIA-ALCL is a lymphoma associated with the capsule around certain implants, more strongly with higher-grade textures. It is not breast cancer in the ordinary ductal sense. It often presents as late swelling, a seroma years after surgery. It is uncommon. Uncommon is not the same as theoretical, and it is not a reason to whisper.

The TGA’s public actions — reviews, suspensions, cancellations, updated informed-consent expectations — changed the tray in Sydney more effectively than any essay. Surgeons who liked a particular textured device had to stop, substitute, or explain a remaining option in new language. Patients already living with textured implants were told, correctly, that routine removal is not an automatic next step. Surveillance and symptom awareness are.

We go into the disease more carefully in BIA-ALCL: an Australian briefing. This piece is about the surface politics that now sit in every consult.

What you should hear in the rooms

A contemporary explanation sounds like this: here is the device I propose; here is its surface; here is why I am not using the device I used in 2016; here is how we would notice a late seroma; here is how we register you with the Australian Breast Device Registry. If your surgeon cannot say those sentences, the surface conversation has not happened.

Ask what they do for patients who already have older textured devices and feel well. The honest answer is usually watchful: no feverish rush to theatre, no dismissal of new swelling. Panic and complacency are both forms of poor care.

Contracture, rotation and the reasons texture existed

Texture was not invented to annoy a regulator. It was a response to capsules that squeezed, and to shaped implants that rotated. Those problems did not vanish when certain textures left the market. They migrated. Smooth devices in a sloppy pocket drift. Smooth devices under a thin cover can ripple. Anatomical implants without a sticky surface ask more of pocket craft.

This is why shape and placement belong in the same afternoon as surface. Isolating one variable is how brochures work, not how chests work.

Polyurethane and other remaining special cases

Some Australian surgeons still discuss polyurethane-covered implants for complex revision or a contracture-prone history. These devices have enthusiastic supporters and a need for specific counselling. They are not a loophole around the ALCL conversation. They are another surface with its own evidence, registry implications and feel.

If polyurethane is offered as a secret superior option that “clinics don’t want you to know about”, leave. If it is offered as a niche tool with references and a clear why-you, stay and take notes.

How to read a brand card

Bring the card home. Search the TGA’s public information for the product name, not the clinic’s nickname. Ask whether the device is used in reconstruction as well as cosmetics — a weak signal, but a signal, of how widely it is trusted. Ask how many the surgeon placed last year. A device they use twice a year is a hobby. A device they use weekly is a practice.

Then read the registry, AHPRA and the TGA so the paperwork has a home in your head.

Living with a surface you did not choose

Plenty of readers of this journal already have implants from a previous decade. You cannot retrofit a smooth shell onto a textured one without surgery. You can learn the symptoms that matter, keep your implant card, tell the radiographer at screening, and treat late unilateral swelling as a reason to call, not a reason to search forums at 1 a.m. only.

Surface is not a personality. It is a regulatory and biological interface. In Australia it is also a history lesson. Ask for the lesson in the consult, not after the invoice.

How to talk to friends who had surgery in another decade

They may have textured devices and feel well. They do not need a midnight lecture. They do need the late-swelling rule and a GP who will not wave it away. Share the ALCL briefing if they want a page, not a thread.

If they are choosing revision for size or a lift, surface becomes a live choice again. That is a good moment to update the tray to whatever their surgeon now considers defensible, and to put them on the registry if they never were.

The culture changed. The people living in older decisions deserve information, not fashion shame.

Ask your surgeon to write the surface name on the same page as the volume. A card that only says a brand is a half-sentence. Future you, at a screening desk or a revision consult, will want the whole sentence.